TABLE 3.

Clinical trials using checkpoint inhibitors in HIV-infected populations

Trial	Study drug	Target(s)	Population	Phase
NCT03787095	Cemiplimab	PD1	Suppressed HIV on ART	1/2
NCT03239899	Pembrolizumab	PD-1	CNS HIV reservoir	1
NCT03367754	Pembrolizumab	PD-1	HIV with low CD4+ cell count	1
NCT02595866	Pembrolizumab	PD-1	HIV and malignant neoplasms	1
NCT03304093	Nivolumab	PD-1	HIV and non-small-cell lung cancer	2
NCT02408861	Nivolumab and ipilimumab	PD-1, CTLA-4	HIV and malignant neoplasms	1
NCT03316274	Nivolumab	PD-1	HIV and Kaposi sarcoma	1
NCT03407105	Ipilimumab	CTLA-4	HIV	1
NCT03094286	Durvalumab	PD-L1	HIV and solid tumors	2